Literature DB >> 17668898

Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes.

Gregory A Stoloff1, Wilson Caparros-Wanderley.   

Abstract

Influenza causes yearly epidemics of mild disease and, occasionally, pandemics with millions of fatalities. Currently, no vaccine is effective against all influenza strains. Analysis of influenza sequences from animal and human isolates using CLUSTALW and a novel proprietary epitope prediction algorithm identified six conserved T cell-reactive regions in several proteins. Immunisation of transgenic mice with a preparation of these six regions as chemically synthesised peptides (FLU-v) induced a specific HLA-A*0201-mediated CD8(+) T cell response. This T cell population also reacted against human cells infected with three non-related influenza strains, confirming that the identified regions contain epitopes naturally presented by infected human cells and conserved amongst non-related viruses. Moreover, FLU-v immunisation significantly increased survival of transgenic mice against lethal challenge with influenza. Overall, FLU-v represents a promising influenza vaccine candidate, obviating the need for yearly vaccinations and allowing the stockpiling and initiation of a worldwide vaccination program in advance of a pandemic outbreak.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668898     DOI: 10.1002/eji.200737254

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  30 in total

1.  Protection by universal influenza vaccine is mediated by memory CD4 T cells.

Authors:  Sophie A Valkenburg; Olive T W Li; Athena Li; Maireid Bull; Thomas A Waldmann; Liyanage P Perera; Malik Peiris; Leo L M Poon
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

2.  The proteosomal degradation of fusion proteins cannot be predicted from the proteosome susceptibility of their individual components.

Authors:  Petr O Ilyinskii; Anatoli B Meriin; Vladimir L Gabai; Evgeny V Usachev; Alexei G Prilipov; Galini Thoidis; Alexander M Shneider
Journal:  Protein Sci       Date:  2008-04-14       Impact factor: 6.725

3.  A Synthetic Influenza Virus Vaccine Induces a Cellular Immune Response That Correlates with Reduction in Symptomatology and Virus Shedding in a Randomized Phase Ib Live-Virus Challenge in Humans.

Authors:  Olga Pleguezuelos; Stuart Robinson; Ana Fernández; Gregory A Stoloff; Alex Mann; Anthony Gilbert; Ganesh Balaratnam; Tom Wilkinson; Rob Lambkin-Williams; John Oxford; Wilson Caparrós-Wanderley
Journal:  Clin Vaccine Immunol       Date:  2015-05-20

4.  Highly conserved hemagglutinin peptides of H1N1 influenza virus elicit immune response.

Authors:  Neha Lohia; Manoj Baranwal
Journal:  3 Biotech       Date:  2018-11-20       Impact factor: 2.406

5.  Steric recognition of T-cell receptor contact residues is required to map mutant epitopes by immunoinformatical programmes.

Authors:  Shiou-Chih Hsu; Chih-Peng Chang; Chao-Yuan Tsai; Shih-Hung Hsieh; Betty A Wu-Hsieh; Yu-Shu Lo; Jinn-Moon Yang
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

6.  Meta-Analysis and Potential Role of Preexisting Heterosubtypic Cellular Immunity Based on Variations in Disease Severity Outcomes for Influenza Live Viral Challenges in Humans.

Authors:  Olga Pleguezuelos; Stuart Robinson; Ana Fernandez; Gregory A Stoloff; Wilson Caparrós-Wanderley
Journal:  Clin Vaccine Immunol       Date:  2015-06-17

Review 7.  Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing.

Authors:  John S Oxford
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

8.  Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice.

Authors:  Jeff Alexander; Pamuk Bilsel; Marie-France del Guercio; Stephani Stewart; Aleksandra Marinkovic-Petrovic; Scott Southwood; Claire Crimi; Lo Vang; Les Walker; Glenn Ishioka; Vivek Chitnis; Alessandro Sette; Erika Assarsson; Drew Hannaman; Jason Botten; Mark J Newman
Journal:  Vaccine       Date:  2009-11-04       Impact factor: 3.641

9.  Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity in vivo.

Authors:  Sweety Samal; Tripti Shrivastava; Praveen Sonkusre; Zaigham Abbas Rizvi; Rajesh Kumar; Shubbir Ahmed; Preeti Vishwakarma; Naveen Yadav; Manish Bansal; Kanchana Chauhan; Sebanta Pokhrel; Supratik Das; Padmakar Tambare; Amit Awasthi
Journal:  J Biol Chem       Date:  2020-08-13       Impact factor: 5.157

10.  CD8+ T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.

Authors:  Luca Hensen; Patricia T Illing; E Bridie Clemens; Thi H O Nguyen; Marios Koutsakos; Carolien E van de Sandt; Nicole A Mifsud; Andrea T Nguyen; Christopher Szeto; Brendon Y Chua; Hanim Halim; Simone Rizzetto; Fabio Luciani; Liyen Loh; Emma J Grant; Phillipa M Saunders; Andrew G Brooks; Steve Rockman; Tom C Kotsimbos; Allen C Cheng; Michael Richards; Glen P Westall; Linda M Wakim; Thomas Loudovaris; Stuart I Mannering; Michael Elliott; Stuart G Tangye; David C Jackson; Katie L Flanagan; Jamie Rossjohn; Stephanie Gras; Jane Davies; Adrian Miller; Steven Y C Tong; Anthony W Purcell; Katherine Kedzierska
Journal:  Nat Commun       Date:  2021-05-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.